Appendix Table C17. KQ1 Outcome II. Transfusion: Darbepoetin versus control

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study ID** | **Dosage** | **Treatment n** | **Treatment N** | **Proportion (%)** | **Control n** | **Control N** | **Proportion (%)** | **First 4 wks included in analysis?** | **Comments** |
| **Baseline Hb below < 10g/dL** | | | | | | | | | |
| **Hedenus 2003** | 2.25 µg/kg/qw | 52 | 167 | 31.14% | 79 | 165 | 47.88% | excluded | derived from K-M estimates, arm a: 31%( 95% CI 24-38), N=167; 48% (95% CI 41%-56%), N=165 |
| **Kotasek 2003a** | 4.5 μg/kg Q3W | 8 | 30 | 26.67% | 23 | 50 | 46% | excluded | arm a: 25% (9%-41%), N=30; control 46% (32%-61%), N=50 |
| **Kotasek 2003b** | 6.75 μg/kg Q3W | 5 | 17 | 29.41% |  |  |  |  | arm b: 28% (7%-51%), N=17 |
| **Kotasek 2003c** | 9.0 μg/kg Q3W | 12 | 41 | 29.27% |  |  |  |  | arm c: 30% (16%-44%), N=41 |
| **Kotasek 2003d** | 12.0 μg/kg Q3W | 7 | 27 | 25.93% |  |  |  |  | arm d: 26% (7.5%-41%), N=27 |
| **Kotasek 2003e** | 13.5 μg/kg Q3W | 9 | 35 | 25.71% |  |  |  |  | arm e: 27% (11%-40%), N=35 |
| **Kotasek 2003f** | 15 μg/kg Q3W | 7 | 38 | 18.42% |  |  |  |  | arm f: 19% (6%-32%), N=38 |

Appendix Table C17. KQ1 Outcome II. Transfusion: Darbepoetin versus Control, (continued)

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study ID** | **Dosage** | **Treatment n** | **Treatment N** | **Proportion (%)** | **Control n** | **Control N** | **Proportion (%)** | **First 4 wks included in analysis?** | **Comments** |
| **Baseline Hb 10-12g/dL** | | | | | | | | | |
| **Hernandez 2009** | 300 µg Q3W | 58 | 193 | 30.05% | 91 | 193 | 47.15% | included |  |
| **Pirker 2008** | 300 µg Q4W, after 4 wks changed to Q3W sc | 52 | 298 | 17.45% | 116 | 298 | 38.93% | unclear |  |
| Untch 2011 | NR | 1 | 356 | <1% | 0 | 377 | 0.00% | unclear |  |
| Vansteen.\_FDA report | 2.25 µg/kg qw | 53 | 156 | 33.97% | 89 | 158 | 56.33% | included |  |